The FDA approves Aduhelm (aducanumab) to treat patients with Alzheimer’s disease

FDA approves Aduhelm (aducanumab) using the accelerated approval pathway used for drugs treating serious or life-threatening illness that provide a meaningful therapeutic advantage over existing treatments. The drug is shown to have an effect and reasonably likely to have a clinical benefit to patients, yet there remains some uncertainty about the drug’s true clinical benefit.